Compared with standard therapy of lenalidomide and dexamethasone, the addition of carfilzomib improved survival, without increasing the risk of...
Myeloma NZ
Update on diagnosis, risk‐stratification and management
Multiple myeloma accounts for approximately 10% of hematologic malignancies. The diagnosis requires ≥10% clonal bone marrow plasma cells or a biopsy...
Trial represents ‘bold move’ for treatment of newly diagnosed myeloma
Researchers at The University of Alabama at Birmingham are recruiting for a phase 2 clinical trial designed to offer an innovative treatment...
Patient Seminar: From 45 South – The Otago Myeloma Research Trust
Presented by Dr Ian Morison on 1 August, 2018 Watch the video below
Access to prescription drug coverage improves myeloma survival
Patients with myeloma with outpatient prescription drug coverage were more likely to receive oral targeted agents instead of parenteral...
Clarithromycin Plus Bortezomib May Be Ineffective, Toxic in Multiple Myeloma
Clarithromycin plus bortezomib does not confer any additional efficacy and is a toxic combination among patients with multiple myeloma (MM),...
Leukogene Therapeutics receives funding to develop compound for resistant multiple myeloma
A $2 million phase 2 Small Business Technology Transfer (STTR) grant to optimize a promising new compound that has shown efficacy in preclinical...
UK panel rejects CAR T-cell therapy due to cost
An independent body that offers guidance to improve health and social care in England recommended against the use of axicabtagene ciloleucel, one of...
Could a Blood Test Help Clinicians Diagnose Multiple Myeloma Earlier?
There may be a way to detect multiple myeloma (MM) earlier — effectively shortening the longer diagnostic interval that is typically associated with...
Expert Reflects on “Incredible” Data Seen With bb2121 in Heavily Pretreated Myeloma
The deep and durable phase I responses seen with the anti-BCMA chimeric antigen receptor (CAR) T-cell therapy bb2121 in patients with...
Two CAR T-Cell Therapies Greenlighted in Europe
The European Commission has approved the use of Novartis’s tisagenlecleucel (Kymriah) and Gilead’s axicabtagene ciloleucel (Yescarta), two chimeric...
An Integrative Multiomics Approach to Multiple Myeloma
When practicing precision oncology for multiple myeloma, clinicians currently match specific DNA mutations to the optimal targeted therapy. However,...